NASDAQ:NVCT

Nuvectis Pharma Stock Insider Trading

Healthcare > Biotechnology

Buy NVCT

*Your capital is at risk

$9.31

-0.200 (-2.10%)

At Close: Jun 03, 2026

Nuvectis Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.03. In total, the insiders bought 3.33M and sold 5.51K NVCT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.03
● Buy	3.33M shares
● Sell	5.51K shares
98% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jan 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.03. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (98% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 06, 2026 Buy	Common Stock A-Award	Carson Michael J. Vice President, Finance	CEO / President	61 200 Value: $501.8K
Jan 06, 2026 Buy	Common Stock A-Award	Poradosu Enrique Chief Science & Business Off	Officer	150 000 Value: $1.23M
Jan 06, 2026 Buy	Common Stock A-Award	Bentsur Ron Chairman & CEO	CEO / President	150 000 Value: $1.23M
Jan 06, 2026 Buy	Common Stock A-Award	Shemesh Shay Chief Dev. & Ops. Officer	Officer	150 000 Value: $1.23M
Nov 05, 2025 Buy	Common Stock P-Purchase	Kaplan Matthew L. Director	Director	11 000 Value: $64.2K
Nov 05, 2025 Buy	Common Stock P-Purchase	Sanchez Juan Director	Director	13 000 Value: $75.3K
Nov 05, 2025 Buy	Common Stock P-Purchase	Bentsur Ron Chairman & CEO	CEO / President	5 000 Value: $28.6K
Oct 27, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	72 836 Value: $457.4K
Oct 24, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	35 034 Value: $215.5K
Oct 23, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	46 900 Value: $284.2K
Sep 22, 2025 Buy	Common Stock	Sanchez Juan Director	Director	0 Value: $0
Sep 22, 2025 Buy	Common Stock	Sanchez Juan Director	Director	0 Value: $0
Sep 22, 2025 Buy	Common Stock	Sanchez Juan Director	Director	0 Value: $0
Sep 22, 2025 Buy	Common Stock A-Award	Sanchez Juan Director	Director	30 000 Value: $192.9K
Jun 20, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	5 603 Value: $44.8K
Jun 20, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	5 603 Value: $44.8K
Jun 18, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	28 043 Value: $225.7K
Jun 18, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	28 043 Value: $225.7K
Jun 17, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	5 399 Value: $43.8K
Jun 17, 2025 Buy	Common Stock P-Purchase	Mosseri Marlio Charles 10 Percent Owner	10% Owner	5 399 Value: $43.8K
Jun 12, 2025 Buy	Common Stock A-Award	Kaplan Matthew L. Director	Director	30 000 Value: $264.9K
Jun 12, 2025 Buy	Common Stock A-Award	Oliviero James F Iii Director	Director	30 000 Value: $264.9K
Jun 12, 2025 Buy	Common Stock A-Award	Hoberman Kenneth Director	Director	30 000 Value: $264.9K
Jun 12, 2025 Buy	Common Stock A-Award	Hoberman Kenneth Director	Director	30 000 Value: $264.9K
Jun 12, 2025 Buy	Common Stock A-Award	Oliviero James F Iii Director	Director	30 000 Value: $264.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NUVECTIS PHARMA, INC.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey....

Read Full Profile Here